Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study

American Journal of Kidney Diseases

Volumn 42, Issue 1 SUPPL. 2, 2003, Pages 108-116

  Longenecker, J Craig ^a   Coresh, Josef ^b   Marcovina, Santica M ^b   Powe, Neil R ^b   Levey, Andrew S ^b   Giaculli, Federico ^b   Fink, Nancy E ^b   Klag, Michael J ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b NONE

Author keywords

Apolipoprotein(a) apo(a) ; Cardiovascular disease (CVD); End stage renal disease (ESRD); Lipoprotein(a) Lp(a)

Indexed keywords

GLYCOPROTEIN; LIPOPROTEIN A;

ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; DIALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PERIPHERAL VASCULAR DISEASE; RISK;

EID: 0038048066     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00413-X     Document Type: Article

References (39)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119, 1998 (suppl 3)
2. Churchill D, Taylor D, Cook R, et al: Canadian hemodialysis morbidity study. Am J Kidney Dis 19:214-234, 1992
3. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799-805, 1998
4. Coresh J, Longenecker JC, Miller ER, Young HJ, Klag MJ: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:S24-S30, 1998 (suppl 3)
5. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082-1085, 2000
6. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP: Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41:246-255, 1995
7. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H: Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 37:2569-2585, 1996
8. Kronenberg F, Konig P, Neyer U, et al: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120, 1995
9. Petersen LJ, Ringsdal VS, Ladefoged SD, Baslund B, Hansen PR: Anticardiolipin antibodies and lipoprotein(a) levels in patients with chronic renal failure treated with dialysis: Associations with atherothrombotic disease. Int J Artif Organs 19:339-342, 1996
10. Del-Cura J, Gil-Paraiso A, Borque L, Carazo ME, Maside C, Sanchez-Casajus A: Lipoprotein(a) in chronic renal failure patients undergoing hemodialysis: Does it have an independent role in the development of further cardiovascular complications? Nephron 65:644-645, 1993 (letter)
11. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA: Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 10:354-357, 1995
12. Koch M, Kutkuhn B, Trenkwalder E, et al: Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8:1889-1898, 1997
13. Kronenberg F, Neyer U, Lhotta K, et al: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up. J Am Soc Nephrol 10: 1027-1036, 1999
14. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
15. Kronenberg F, Kronenberg MF, Kiechl S, et al: Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study. Circulation 100:1154-1160, 1999
16. Marcovina SM, Koschinsky ML: Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis? Circulation 100:1151-1153, 1999
17. Powe N, Klag M, Sadler J, et al: Choices for Healthy Outcomes in Caring for End-Stage Renal Disease. Semin Dial 9:9-11, 1996
18. Greenfield S, Sullivan L, Silliman RA, Dukes K, Kaplan SH: Principles and practice of case mix adjustment: Applications to end stage renal disease. Am J Kidney Dis 24:298-307, 1994
19. Miskulin DC, Meyer KB, Athienites NV, et al: Comorbidity and other factors associated with modality selection in incident dialysis patients: The CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease. Am J Kidney Dis 39:324-336, 2002
20. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ: Identification of 34 apolipoprotein(a) isoforms: Differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 191:1192-1196, 1993
21. Marcovina SM, Hobbs HH, Albers JJ: Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: Basis for a standardized isoform nomenclature. Clin Chem 42:436-439, 1996
22. US Renal Data System: USRDS 1999 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999
23. Wild SH, Fortmann SP, Marcovina SM: A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 17:239-245, 1997
24. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G: Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: Evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 89:1040-1046, 1992
25. Willeit J, Kiechl S, Santer P, et al: Lipoprotein(a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: The Bruneck study. Stroke 26:1582-1587, 1995
26. Goldwasser P, Michel MA, Collier J, et al: Prealbumin and lipoprotein(a) in hemodialysis: Relationships with patient and vascular access survival. Am J Kidney Dis 22:215-225, 1993
27. Noma A, Abe A, Maeda S, et al: Lp(a): An acute-phase reactant? Chem Phys Lipids 67-68:411-417, 1994
28. Klausen IC, Sjol A, Hansen PS, et al: Apolipoprotein(a) isoforms and coronary heart disease in men: A nested case-control study. Atherosclerosis 132:77-84, 1997
29. Hahmann HW, Schatzer-Klotz D, Bunte T, Becker D, Schieffer HJ: The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: Differences between men and women. Atherosclerosis 144:221-228, 1999
30. Sunayama S, Daida H, Mokuno H, et al: Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age. Circulation 94:1263-1268, 1996
31. Gazzaruso C, Garzaniti A, Buscaglia P, et al: Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol 33:157-163, 1999
32. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K, et al: Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 95:329-334, 1997
33. Hervio L, Chapman MJ, Thillet J, Loyau S, Angles-Cano E: Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 82:392-397, 1993
34. Kronenberg F, Kathrein H, Konig P, et al: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14:1405-1411, 1994
35. Schreiner PJ: Lipoprotein(a) as a risk factor for preclinical atherosclerotic disease in a biracial cohort: The Atherosclerosis Risk in Communities (ARIC) Study. Chem Phys Lipids 67-68:405-410, 1994
36. Moliterno DJ, Jokinen EV, Miserez AR, et al: No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 15:850-855, 1995
37. Sorrentino MJ, Vielhauer C, Eisenbart JD, Fless GM, Scanu AM, Feldman T: Plasma lipoprotein(a) protein concentration and coronary artery disease in black patients compared with white patients. Am J Med 93:658-662, 1992
38. Dahlen GH, Srinivasan SR, Stenlund H, Wattigney WA, Wall S, Berenson GS: The importance of serum lipoprotein(a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States. J Intern Med 244:417-424, 1998
39. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G: Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 16:1568-1572, 1996